We recently compiled a list of the 10 AI News That Broke The Internet. In this article, we are going to take a look at where Lantern Pharma Inc. (NASDAQ:LTRN) stands against the other AI stocks.
Should original content contributors be paid every time large language models use their work? OpenAI CEO Sam Altman believes they should, much like Name, Image, and Likeness (NIL) deals for college athletes, he said on Wednesday at the New York Times’ DealBook Summit.
“I think we do need a new [standard] for how creators are going to get rewarded. We need to find new economic models where creators can have new revenue streams”.
-Sam Altman
READ ALSO: 10 Buzzing AI Stocks Making Headlines and Top 10 AI News Stories For The Weekend
Even though developing such an economic model will be complex, it is unclear how people getting paid for their original work could become a norm in the future even if it does. The news comes amidst ChatGPT, Altman’s AI chatbot, which has itself been under fire numerous times over the years over copyright infringement and unpermitted use of published articles.
“A particular passion of mine has always been, can we figure out how to do micropayments where, if you generate a story in the style of [a writer, they] can opt into that … and get paid for it.”
-Altman.
Regardless of Altman’s company facing criticism over copyright infringement concerns and ethical debates surrounding its AI models, the company continues to push boundaries in AI innovation, introducing groundbreaking tools and features that redefine the tech landscape. In its latest, OpenAI has introduced its buzzy AI video-generation tool, Sora, on Monday, December 9th.
Working similar to OpenAI’s image-generation AI tool, DALL-E, Sora will be able to develop a high-definition video clip each time a user types out a desired scene. The video generation tool will also be able to generate video clips inspired by still images and extend existing videos or fill in missing frames. As per OpenAI’s YouTube live stream, the tool will debut to U.S. users as well as to “most countries internationally” on Monday, December 9th. However, it also said that there is “no timeline” yet for launching the tool in Europe and the U.K., as well as some other countries.
In October, the company closed its latest funding round with a valuation of $157 billion, securing $6.6 billion from a wide range of investment firms and major tech companies. All of the company’s strategic initiatives and funding are part of a thoughtful growth plan for OpenAI as the company competes with other strong AI startups such as Anthropic, Elon Musk’s xAI, and other tech giants.
For this article, we selected AI stocks by going through news articles, stock analysis, and press releases. These stocks are also popular among hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
A researcher standing in a modern laboratory, surrounded by scientific equipment.
Lantern Pharma Inc. (NASDAQ:LTRN)
Number of Hedge Fund Holders: 3
Lantern Pharma Inc. (NASDAQ:LTRN) is a clinical-stage biotechnology company developing targeted cancer therapies using its proprietary RADR® AI platform. On December 9, the company announced that it had begun its Phase 2 HARMONIC™ clinical trial, enrolling its first patient in Taiwan. The Harmonic™ is a clinical trial investigating the overall and progression-free survival of never-smoker patients with relapsed advanced non-small cell lung cancer (NSCLC) after treatment with the investigational new drug LP-300 in combination with chemotherapy. The study will evaluate LP-300 in never-smoker patients with non-small cell lung cancer (NSCLC) who have progressed after receiving treatment with tyrosine kinase inhibitors (TKIs), a targeted therapy drug. The enrollment of the first patient in Taiwan, a key region for the study, marks an important milestone in the expansion of their HARMONIC trial.
“The enrollment of our first patient in Taiwan marks another important milestone in the expansion of our HARMONIC™ trial. The extremely high proportion of never-smoker lung cancer patients in Taiwan makes this region important for accelerating our enrollment with the objective of addressing a critical unmet need in a population where this disease has an outsized impact”.
-Panna Sharma, President and CEO of Lantern Pharma.
Overall, LTRN ranks 10th on our list of AI news that broke the internet. While we acknowledge the potential of LTRN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LTRN but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.
Disclosure: None. This article is originally published at Insider Monkey.
